Truveta , the Bellevue‑based health data company, announced the launch of Truveta Intelligence, an AI‑powered tool that can answer natural‑language queries about patient populations in minutes rather than months. The move is poised to accelerate drug‑development timelines and real‑time clinical insights. Truveta has built a network of 30 health‑system partners that provide de‑identified clinical records for more than 130 million patients, representing over 18 % of daily U.S. clinical care. The platform’s live data queries distinguish it from other AI tools that rely on published literature. Truveta Intelligence is now available to existing Truveta Data subscribers, including life‑sciences companies and health systems. The company, founded in 2020, has raised $515 million to date and employs more than 400 people. In January 2025, it secured a $320 million round led by Regeneron , Illumina , and 17 health systems, pushing its valuation above $1 billion. By providing near real‑time answers, Truveta Intelligence could help drug makers gauge how new therapies perform, enable health systems to detect outcome variations, and allow public‑health researchers to spot emerging trends earlier. Truveta was founded in 2020 with roots at Providence, the large health system based in Washington state. Terry Myerson, a former Microsoft executive vice president who led the company’s Windows and Devices Group, has led the company as CEO since its inception. The company is ranked No. 3 on the GeekWire 200.